Can a common bone drug help HIV patients fight osteoporosis?
NCT ID NCT00120757
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether alendronate, a drug used for osteoporosis, can improve bone density in people with HIV. 140 participants received either alendronate or a placebo, along with calcium and vitamin D, for 2 years. The goal was to see if the drug could strengthen bones and reduce fracture risk in this population.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital Necker service des Maladies Infectieuses
Paris, 75015, France
-
Service de Medecine Interne hopital Avicenne
Bobigny, 93009 cedex, France
-
Service de Rhumatologie hopital Pitie-Salpetriere
Paris, 75013, France